收费全文 | 335150篇 |
免费 | 28637篇 |
国内免费 | 12104篇 |
耳鼻咽喉 | 2509篇 |
儿科学 | 5080篇 |
妇产科学 | 3878篇 |
基础医学 | 54245篇 |
口腔科学 | 6298篇 |
临床医学 | 23894篇 |
内科学 | 62025篇 |
皮肤病学 | 4969篇 |
神经病学 | 26017篇 |
特种医学 | 7689篇 |
外国民族医学 | 82篇 |
外科学 | 24482篇 |
综合类 | 41481篇 |
现状与发展 | 40篇 |
一般理论 | 8篇 |
预防医学 | 19064篇 |
眼科学 | 3812篇 |
药学 | 48995篇 |
81篇 | |
中国医学 | 12849篇 |
肿瘤学 | 28393篇 |
2024年 | 858篇 |
2023年 | 5835篇 |
2022年 | 12825篇 |
2021年 | 15574篇 |
2020年 | 12447篇 |
2019年 | 12173篇 |
2018年 | 11696篇 |
2017年 | 11423篇 |
2016年 | 11257篇 |
2015年 | 12929篇 |
2014年 | 19740篇 |
2013年 | 21645篇 |
2012年 | 18747篇 |
2011年 | 21834篇 |
2010年 | 17851篇 |
2009年 | 18079篇 |
2008年 | 17646篇 |
2007年 | 16155篇 |
2006年 | 14218篇 |
2005年 | 12432篇 |
2004年 | 10537篇 |
2003年 | 9260篇 |
2002年 | 7399篇 |
2001年 | 6348篇 |
2000年 | 5449篇 |
1999年 | 4860篇 |
1998年 | 4380篇 |
1997年 | 4195篇 |
1996年 | 3727篇 |
1995年 | 3407篇 |
1994年 | 3035篇 |
1993年 | 2602篇 |
1992年 | 2218篇 |
1991年 | 1988篇 |
1990年 | 1674篇 |
1989年 | 1402篇 |
1988年 | 1364篇 |
1987年 | 1159篇 |
1986年 | 1169篇 |
1985年 | 2012篇 |
1984年 | 2052篇 |
1983年 | 1521篇 |
1982年 | 1558篇 |
1981年 | 1319篇 |
1980年 | 1190篇 |
1979年 | 1029篇 |
1978年 | 758篇 |
1977年 | 645篇 |
1976年 | 706篇 |
1975年 | 539篇 |
Research design and methods: This multicenter, open-label, single-group, prospective interventional study evaluated changes in total gait-related scores of the Part II/III Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and Freezing of Gait Questionnaire (FOG-Q) in 31 Parkinson’s disease patients treated with istradefylline. Gait analysis by portable gait rhythmogram was performed.
Results: MDS-UPDRS Part III gait-related total scores significantly decreased at Weeks 4–12 from baseline with significant improvements in gait, freezing of gait, and postural stability. Significant decreases in MDS-UPDRS Part II total scores and individual item scores at Week 12 indicated improved daily living activities. At Week 12, there were significant improvements in FOG-Q, new FOG-Q, and overall movement per 48 h measured by portable gait rhythmogram. Adverse events occurred in 7/31 patients.
Conclusions: Istradefylline improved gait disorders in Parkinson’s disease patients complicated with freezing of gait, improving their quality of life. No unexpected adverse drug reactions were identified.
Trial registration: UMIN-CTR (UMIN000020288). 相似文献
Design: Forty-two patients participating in the Task Shifting Strategy for Hypertension program (23 males, 19 females, and mean age 61. 7 years) completed in-depth, qualitative interviews. Interviews were transcribed, and key words and phrases were extracted and coded using the PEN-3 Cultural Model as a guide through open and axial coding techniques, thus allowing rich exploration of the data.
Results: Emergent themes included patients’ perceptions of hypertension, which encompassed misperceptions of hypertension and blood pressure control. Additional themes included enablers and barriers to hypertension management, and how the intervention nurtured lifestyle change associated with blood pressure control. Primary enabling factors included the supportive nature of TASSH nurses, while notable barriers were financial constraints and difficulty accessing medication. Nurturing factors included the motivational interviewing and patient counseling which instilled confidence in the patients that they could make lasting behavior changes.
Conclusions: This study offers a unique perspective of blood pressure control by examining how patients view an on-going task-shifting initiative for hypertension management. The results of this study shed light on factors that can help and hinder individuals in low-resource settings with long-term blood pressure management. 相似文献
Areas covered: This review covers the mechanism of action, safety and efficacy of sacituzumab govitecan in patients with previously treated, metastatic TNBC. Additionally, efficacy data in other epithelial malignancies is included based on a PubMed search for ‘sacituzumab govitecan’ and ‘clinical trial’.
Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. 相似文献